The board of directors of Shanghai Junshi Biosciences Co., Ltd. announced that the Company has received the Drug Registration Certificate issued by the National Medical Products Administration. The supplemental new drug application (the "NDA") for the Company's product toripalimab (trade name: TUOYI®?, product code: JS001) in combination with paclitaxel for injection (albumin-bound) for the first-line treatment of recurrent or metastatic triple-negative breast cancer ("TNBC") with a well-validated test to evaluate PD-L1 positive (CPS 1) has been approved. This is the 10th indication for toripalimab approved in Chinese mainland.